Ivermectin’s Effectiveness Proven Again; 72% Efficacy
800,000 people died in the USA for nothing
By Igor Chudov | January 11, 2023
You are not a horse! You are not a cow! That’s what the FDA told us to dissuade us from taking Ivermectin.
Fortunately, we are also not sheep and did not believe the FDA. Many of us stocked up on Ivermectin, and most found it helpful. While I did not use it when I had my Covid in Nov 2020, it worked great for my wife in Dec 2021 and other family members during the summer of 2022.
Ivermectin, a cheap and safe generic medication, was of little interest to profit-minded pharmaceutical giants like Pfizer and Merck. Therefore, they conspired with the FDA to lie that it did not work and instead pushed expensive Covid vaccines and non-working drugs like mutagenic Molnupiravir and rebound-causing Paxlovid.
MedinCell conducted a randomized controlled trial of their version of Ivermectin and found that it reduces Covid infections by 72%!
The study was very well designed because the participants were EXPOSED to the Covid infection within five days. Given the exposure, the outcomes were more likely to happen and thus were easier to compare between groups, giving the trial greater statistical power.
The 72% reduction in infection is much MORE effective than the “covid vaccine.”
The trial encompassed the period of Mar-Nov 2022, thus giving us the real-world effectiveness of Ivermectin against the Omicron variant.
While I am happy at the finding, there are several things to be NOT happy about.
- If we are to believe official numbers, about 1,121,000 people died of Covid in the USA. Given published effectiveness estimates of Ivermectin coming from honest studies, Ivermectin could have saved eight hundred thousand of those lives. The intentional suppression of Ivermectin cost us so dearly.
- Given a 72% reduction in infection, natural immunity with Ivermectin would likely have stopped the pandemic entirely in 2020.
- Had Ivermectin been recognized as an effective antiviral, the “Covid vaccines” could not get EUA approval, and thus we would avoid thousands of vaccine victims and destroyed immune systems.
- Second-largest Democratic donor and the largest crypto thief Sam Bankman-Fried donated 18 million dollars to the Together trial after it falsely demonstrated a finding that Democrat-aligned Covid vaccine pushers wanted, namely that Ivermectin allegedly was useless.
The good news here is that Ivermectin works.
Here are some of my other articles about Ivermectin — with honest trials showing a comparable reduction in illness and death.
So, thousands of people died of Covid. Thousands of people died of Covid vaccines. The pandemic, prolonged by vaccination, is raging and reinfects people with immunity disabled by mystery genetic treatments. My prediction from last March, unfortunately, is coming true.
AIDS-Like “Chronic Covid” is Taking Over Europe, Australia and NZ
All of this happened because of the recklessness and greed of the biomedical-industrial complex, which developed Sars-Cov-2 and then pushed an unproven, ineffective vaccine that worsened the pandemic.
While the above paragraph is upsetting, the good news is that Ivermectin was validated, and “we have the tools” to manage a Covid infection or exposure.
Lastly, take a minute to think about millions of victims of suppression of Ivermectin worldwide, who died to make a few companies and foundations richer and more powerful.
Will Ivermectin ever be recommended officially? And do we even care about such approval if we can still order it online?
US House Establishes Panel to Investigate Potential Weaponization of Federal Government
Samizdat – 11.01.2023
WASHINGTON – The US House of Representatives on Tuesday passed a resolution establishing a select subcommittee to investigate whether components of the federal government have been weaponized against everyday citizens.
House lawmakers passed a resolution establishing the special Judiciary Committee panel in a vote of 221-211, falling along partisan lines.
“Congress hasn’t kept pace with the federal government’s potential to abuse new technology, and we need to better understand how US intelligence agencies work with each other and with the private sector to collect information on Americans or to undermine their fundamental constitutional rights,” House Majority Leader Steve Scalise said in a statement on the panel.
The subcommittee will investigate how the FBI, Justice Department, Department of Homeland Security and other executive branch agencies obtain information from and provide information to the private sector and other agencies to facilitate actions against US citizens.
The panel will be granted access to information shared with the House Intelligence Committee and the authority to review ongoing criminal investigations. The panel is styled after the Church Committee of 1975, which conducted similar oversight of federal agencies.
House Speaker Kevin McCarthy will name 13 members to the subcommittee, including five Democrats in consultation with Minority Leader Hakeem Jeffries.
A few months after their 16 year old student dies running track, Amherst school superintendent admits they’ll hold a COVID vaccine clinic for students and be paid $2,000 to do so
By Meryl Nass | January 10, 2023
Sacrificing virgins on the altar of the Scientism religion, Amherst MA (population 40,000 but housing 2 colleges and a major university) pledges loyalty to the shot, denying the reality of their own student’s recent death from myocarditis.
The Amherst-Pelham MA school superintendent admitted at a meeting streamed on closed circuit TV tonight that he is putting his students’ lives at risk for thirty pieces of silver.
What is wrong with Amherst, a small city chock full of MDs and PhDs, who are mindlessly going along and increasing their kids’ chance of death? Disclosure: I lived there for ten years. I lectured in the next town 3 days ago.
After losing one high school athlete already to the shot (and the parents of the deceased teenager are an MD and PhD) why aren’t people screaming NO!? What does it take to stop the carnage? If it’s such a great vaccine, why do you need to pay people to take it? The town of Amherst’s COVID vaccine website claims that 91% of the town is fully vaxxed. But the clinics won’t stop, even after everyone knows the darn things don’t work.
According to the NYT and CDC, only 15% of Americans have taken a bivalent booster and only 34% have taken any COVID booster. So a lot of us have figured out the scam. Too bad the good, overeducated people of Amherst haven’t yet.
Alzheimer’s drug approval raises the alarm
Data shows treatment can lead to ‘brain shrinkage’
By Maryanne Demasi, PhD | January 9, 2023
The US Food and Drug Administration (FDA) has granted an accelerated approval of a new treatment for Alzheimer’s disease, which aims to clear toxic amyloid protein build-up in the brain.
At a cost of $26,500 per year in the US (not covered by Medicare or Medicaid), people with early Alzheimer’s disease can receive a twice-monthly monoclonal antibody infusion called lecanemab (marketed as LEQEMBI™), co-developed by Eisai, a Japanese biotech firm, and Biogen.
In the lead up to the FDA’s approval, there was intense lobbying for the drug.
A ‘consensus statement’ signed by over 200 scientists, many of whom had financial ties to the drug companies, described lecanemab as a “foundational gamechanger” for the disease, calling for “no barrier” to the widespread availability of the treatment.
Now that the drug has been approved, advocacy groups like the Alzheimer’s Association, which are heavily funded by the drug industry, have welcomed the news, saying the FDA made “the right decision.”
But critics doubt the benefits of lecanemab outweigh its harms, and are dismayed that the FDA approved the drug without input from its own advisory panel.
Kim Witczak, a drug safety advocate, and member of the FDA’s Psychopharmacologic Drugs Advisory Committee, says she is “shocked” by the latest FDA stunt.
“By approving this new drug without a public advisory committee meeting, the FDA once again has shown a lack of concern for the public, patients, and healthcare providers. Convening its advisory panel would have helped reassure everyone that the FDA’s decision was scientifically sound and transparent,” said Witczak.
“Advisory committee meetings offer the opportunity to discuss the data in an open and public forum, to challenge methods, study endpoints (surrogate vs clinically meaningful), and safety findings before the general committee member discussion. But in this case, none of that was possible,” she added.
The FDA’s accelerated approval process used to green-light lecanemab is known for accepting lower evidentiary standards for drug efficacy, so that patients can gain access to experimental drugs sooner.
Critics say its reminiscent of the FDA’s approval of aducanumab – Biogen’s other Alzheimer’s drug. It was approved on the basis of lowering amyloid protein (a surrogate marker) in the brain, despite no clinically meaningful benefit for patients.
At the time, the controversial decision led to the resignation of FDA advisory member Aaron Kesselheim, who labelled it “probably the worst drug approval decision in recent U.S. history.”
Linda Furlini, a research ethics advisor based in Montreal, Canada says it essentially gives the rubber stamp to similar drugs down the track. “Once you grant accelerated approval of a drug in that class, then it’s easier to get the second drug, and then the third drug approved.”
Jessica Adams, an expert in drug regulatory affairs, agrees. She said, “Lecanemab’s approval shows the power of precedent in regulatory approvals. This is why I scoff whenever the FDA says it still reviews drugs on a case-by-case basis.”
The industry-funded study published in the New England Journal of Medicine, involving almost 1800 people with early Alzheimer’s disease, found that lecanemab could slow the decline of cognition and function by 27% over 18 months compared to placebo.
They used a “Clinical Dementia Rating” scale to show lecanemab patients declined by 1.21 points compared to 1.66 point in the placebo group – a 0.45 point difference in lecanemab’s favour.
But experts question whether the small difference will have any impact on how the patient actually feels.
Madhav Thambisetty, a neurologist at Johns Hopkins University and the National Institute on Aging said, “The benefit appears to be quite small, and it’s unclear how meaningful this might be for patients.”
In fact, the FDA’s own statistician Dr Tristan Massie was uncertain whether “the treatment effect on amyloid is reasonably likely to predict change on the clinical outcome” and considered the results of the study to be “exploratory”.
As a physician who cares for people with Alzheimer’s disease, Thambisetty spoke about the harms of the drug. “These patients can experience headaches, falls, confusion, vision disturbances and it’s unclear if patients will be able to see obvious benefits on a day-to-day basis,” he said.
The data showed an increased risk of brain bleeds and swelling, i.e. amyloid-related imaging abnormalities (ARIA) occurred in 126 (14.0%) of subjects in the lecanemab group and only 69 (7.7%) of subjects in the placebo group.
This prompted the FDA to include a warning on the drug about the risk of swelling and bleeding in the brain.
The drugmakers have also highlighted that people carrying two copies of the APOE4 gene (which predisposes someone to Alzheimer’s) puts them at a particularly “high risk of life-threatening brain haemorrhage.”
Three deaths have been reported in people taking lecanemab; an 80-yr old phase 3 trial participant who suffered intracranial haemorrhage, a 65-yr old who experienced brain swelling and bleeding and a 79-yr old who reportedly had seizures and brain bleed in the open-label phase of the trial.
Two of the three people who died were taking blood thinners, and experts who reviewed the lecanemab death cases suggested that anticoagulant use may have exacerbated the fatal outcomes.
Furlini’s research career has focused on the need to educate and support caregivers of people with dementia-type illnesses.
“You read the list of side effects – you might have gait problems, you might have brain swelling, visual disturbances… I mean, what are we doing here?” asks Furlini, “The patient is already confused and losing their cognitive capacity. How are these serious side effects helping them? It runs counter to any ethical semblance of what is wanted or expected.”
Thambisetty has also expressed concerns about the “brain shrinkage” seen in trial participants taking either lecanemab or aducanumab – increasing doses of the drug correlate to a decrease in brain volume.
“The observation of brain shrinkage is worrisome because, in the absence of compelling evidence to the contrary, it suggests a potential worsening of degenerative changes in the brains of people with Alzheimer’s disease,” wrote Thambisetty in a recent opinion piece for STAT.
The observation has been explained away by researchers who say that a reduced brain volume is due to the clearance of amyloid protein from the brain. But Thambisetty says there is little empirical evidence to support this theory.
Instead, he points to an Australian study which calculated that the clearance of amyloid plaque from the brain was too small to represent a plausible explanation for the loss of brain volume.
US lawmakers launched an investigation into the FDA after the agency’s controversial approval of aducanumab. Last month, a US House of Representatives panel released the report following an 18-month investigation.
The report said the process was “rife with irregularities” and that FDA officials “inappropriately collaborated” with the drugmaker during the approval process which “exceeded the norm in some respects.”
Representatives from the FDA and Biogen engaged in over 100 phone calls or meetings dating back to 2019 in order to expedite the drug’s approval, which lawmakers say, “consisted of atypical procedures and deviated from the agency’s own guidance.”
The congressional report recommended the agency “must take swift action to ensure that its processes for reviewing future Alzheimer’s disease treatments do not lead to the same doubts about the integrity of FDA’s review.”
But critics now say, it’s too late for an agency that has not taken accountability for its actions.
“These drug approvals have just created confusion, uncertainty, fear and misinformation. Then they wonder why people have no trust in their institutions, like the FDA. The world looks to the FDA for leadership. That it does not fulfill its responsibilities, remains the challenge of our times,” said Furlini.
Furlini has followed this area of research for decades and says the drug industry needs to move on from the ‘amyloid theory’ of Alzheimer’s disease and refocus its attention on other causes.
“After so many years, I’m fed up with the exclusive focus on the amyloid theory to the exclusion of other research theories, it’s a disservice to people with Alzheimer’s, and their families,” said Furlini
“There are a lot of buzzwords and marketing propaganda being put out there. And they justify it by saying that you have to give people hope. But you’re giving people false hope. It plays with people’s emotions, which I find horrendous,” added Furlini.
Twitter censored tweets after pressure from Pfizer director
By Tom Parker | Reclaim The Net | January 9, 2023
A newly released email from the Twitter Files has revealed that Twitter censored a tweet from Dr. Brett Giroir, a board member at the biopharmaceutical company Altesa Biosciences, after it was flagged by Scott Gottlieb, a board member at the pharmaceutical giant Pfizer.
Gottlieb and Giroir both currently serve on the boards of several pharmaceutical companies and have backgrounds in public health. Gottlieb is a former Food and Drug Administration (FDA) commissioner while Giroir is a former Assistant Secretary for Health and former acting Commissioner of the FDA.
Pfizer produces Covid vaccines whereas Altesa Biosciences develops drugs to combat Covid.
In the August 27, 2021 email, which was published by journalist Alex Berenson, Gottlieb complained to Todd O’Boyle, a senior manager on Twitter’s Public Policy team, about a tweet from Giroir that claimed natural immunity to Covid-19 was superior to vaccine immunity.
“This is the kind of stuff that’s corrosive,” Gottlieb wrote. “Here he draws a sweeping conclusion off a single retrospective study in Israel that hasn’t been peer reviewed. But this tweet will end up going viral and driving news coverage.”
According to Berenson, O’Boyle forwarded Gottlieb’s email to Twitter’s Strategic Response team — a team that was tasked with handling complaints from Twitter’s most important employees and users.
Berenson said that O’Boyle didn’t mention that Gottlieb was a Pfizer board member in this email and instead wrote, “Please see this report from the former FDA commissioner.”
An analyst from Twitter’s Strategic Response team quickly found that the tweet didn’t violate any of Twitter’s “misinformation” rules, according to Berenson. However, the tweet was still slapped with a “Misleading” label and had its replies, shares, and likes disabled after Gottlieb’s complaint.
This label and the restrictions still haven’t been removed, even though several high-ranking health officials, such as former White House Covid response coordinator Dr. Deborah Birx, have since questioned the effectiveness of Covid vaccines when it comes to preventing infections.
Berenson also claimed that one week later, on September 3, 2021, Gottlieb complained about a tweet from Covid lockdown and vaccine skeptic Justin Hart.
The Hart tweet that Gottlieb reportedly complained about stated: “Sticks and stones may break my bones but a viral pathogen with a child mortality rate of ~0% has cost our children nearly three years of schooling.”
Berenson alleged that Gottlieb complained about this tweet when the Pfizer Covid vaccine “would soon be approved for children 5 to 11.”
However, Berenson said that this time, Twitter refused to act.
Previous Twitter email releases have revealed that during the same month that Gottlieb was complaining about Giroir’s tweet, he also flagged one of Berenson’s articles to Twitter. Berenson was temporarily suspended from Twitter days after Gottlieb flagged his article.
Gottlieb responded to the revelations about him flagging Giroir’s tweet by claiming that the publication of this email was a “selective disclosure” of his “private communications with Twitter” and that it had stoked “the threat environment” and instigated “more menacing dialogue, with potentially serious consequences.”
Giroir accused Gottlieb of scheming with Twitter to “apparently put corporate interests first not public health.”
The battle between Big Pharma and scientific integrity
Review – Taking on Big Pharma: Dr. Charles Bennett’s Battle
By Julius Getman and Terri LeClercq
Larger-than-life, creative, and fiercely ambitious, Dr. Charlie Bennett has a long history of revealing dangerous side effects of bestselling medicines. In 2006, his meta-analysis of existing data showed that top-selling ESAs (erythropoietin stimulating agents) created previously unrecognized risks, deaths, and serious illness. According to Dr. Steven Rosen, chief medical officer of the City of Hope Cancer treatment center, Bennett “saved more lives than anyone in American medicine.”
Bennett’s work also created enemies: Bennett was accused, on the basis of flimsy evidence, of mishandling government grant money and violating the False Claims Act (also known as the “Whistleblower Act”). Powerful interests within Big Pharma, academia, and law enforcement joined in the attack on Bennett. By 2010, he was forced from his academic position; was besieged by lawsuits; and became the victim of a coordinated, well-funded campaign to discredit him and refute his work. From pharma superstar to disgrace and disrepute in the blink of an eye.
“Taking On Big Pharma” explores Bennett’s achievement and evaluates the charges against him. Exposed is the unsettling relationship between the pharmaceutical industry and academia. The result of more than five years of research and hundreds of hours of interviews with scientists, academicians, and federal prosecutors, this is an unflinching look at how institutions, purportedly devoted to public health and education, can be corrupted for profit — from drug sales or research grants.
‘New US House chief makes pledge on Ukraine aid’
RT | January 8, 2023
Newly elected US House Speaker Kevin McCarthy reportedly won over the final few votes needed to secure the gavel by promising conservative lawmakers that he will help pass legislation that would limit future economic and military aid to Ukraine.
The Kiev compromise was one of the key concessions that McCarthy, a California Republican, accepted to win over recalcitrant colleagues who had opposed his election as speaker, the UK’s Telegraph newspaper reported on Saturday. Republicans won back control of Congress in November’s midterm elections, but it took five days and 15 rounds of voting for speaker – the most since 1860 – to reach enough consensus on who will shepherd the party’s legislative agenda.
Since Russia began its military offensive against Ukraine last February, Congress has approved $100 billion in US aid to Ukraine – much to the chagrin of ‘Freedom Caucus’ lawmakers, such as Republicans Matt Gaetz (Florida) and Lauren Boebert (Colorado). Gaetz led a group of about 20 representatives in opposing McCarthy’s election, at one point nominating former President Donald Trump for the job.
After McCarthy failed to win enough support from fellow Republicans in the first three rounds of voting on Tuesday, Gaetz said, “Today the House didn’t organize. Biggest loser: [Ukrainian President Vladimir] Zelensky. Biggest winner: US Taxpayers.” He had opposed previous aid requests for Kiev, including a $45-billion package approved last month, saying, “Hemorrhaging billions in taxpayer dollars for Ukraine while our country is in crisis is the definition of America last.”
McCarthy, who occasionally wears a Ukrainian flag pin on his lapel, also agreed to congressional rule changes, limits on defense spending and the creation of a committee to investigate “weaponization” of the federal government. In addition, conservatives won a pledge to allow votes on several of their top issues, including border security, congressional term limits and a balanced budget amendment. The new speaker agreed to give Freedom Caucus members key seats on House committees.
Among those panels is the House Rules Committee. As the Telegraph noted, giving Freedom Caucus members leadership roles on the Rules Committee could create “immense hurdles” to passage of additional aid packages for Ukraine.
US regulator fast-tracks dementia drug
RT | January 6, 2023
The US Food and Drug Administration (FDA) on Friday fast-tracked the approval of lecanemab, a drug to treat the early stages of Alzheimer’s disease. Made by Japanese drugmaker Eisai and Biogen and marketed as Leqembi, the drug allegedly delays cognitive decline caused by the disease, though trials have shown some alarming side effects.
While a clinical trial of lecanemab’s efficacy in early Alzheimer’s published in November found it slowed cognitive and functional decline better than a placebo, the researchers noted that it was “associated with adverse events” and recommended “longer trials” to “determine the efficacy and safety of lecanemab in early Alzheimer’s disease” – an unusual call for caution in a study co-funded by the drug’s manufacturers.
Around 17% of those who took lecanemab experienced brain bleeding during the trials, while nearly 13% suffered brain swelling or effusions, compared to 9% and 2% in the placebo group respectively, according to the New England Journal of Medicine study. Some 7% of the trial participants stopped taking the drug due to the side effects.
Lecanemab’s high price point – $26,500 for a year’s worth of treatment – has also raised concerns. The Institute for Clinical and Economic Review suggested $20,600 as the price ceiling, arguing a cost-effective rate could be as low as $8,500. The company suggested it could lower the dosing frequency to cut costs.
Biogen is no stranger to controversy over its Alzheimer’s drugs. In 2021, several FDA board members resigned over concerns that Aduhelm, which the company had developed as the first drug designed to target the plaque buildup then believed to be the underlying cause of Alzheimer’s, had not demonstrated sufficient efficacy in treating moderate-to-severe dementia. While not a single member of the advisory panel responsible for reviewing the drug supported its approval, the FDA did so anyway, side effects and $56,000 annual price tag notwithstanding.
A congressional investigation that concluded last week found the approval process “rife with irregularities,” noting the FDA had “inappropriately collaborated” with the company it was supposed to be regulating.
Last year, it emerged that parts of the research that established the current plaque-based disease model of Alzheimer’s were possibly fraudulent, suggesting that the amyloid plaques found in the patients could be a symptom, rather than the cause, of the illness.
Featured Video
Israel and the Palestinians — It’s about Mind Over Matter
or go to
Aletho News Archives – Video-Images
Book Review
The Greatest Threat to World Peace? A Review of Daniele Ganser’s ‘USA: The Ruthless Empire’
Review by Marilyn Langlois | November 10, 2023
If you regard the United States as perhaps flawed but overall a force for good in the world . . .
If you scoff at the notion that the US, a republic founded on principles of freedom and democracy, has morphed into a world empire, perpetrating assassinations, coups d’état, acts of terror and illegal warfare . . .
If you want to promote peace but haven’t yet explored deceptive events that precipitate US warmongering . . .
. . . here is a volume that will clear the air and paint an honest picture of the significant, not-so-rosy impact US foreign policy and actions have had in the world around us.
USA: The Ruthless Empire, by Swiss historian and peace researcher Daniele Ganser, is the newly published English language translation of his book Imperium USA, originally written in German and published in 2020. Here is a summary of key points — including some lesser-known ones — along with remedies for a more peaceful future, that are covered in the book. … continue
Blog Roll
Aletho News- US bill to grant Americans serving in Israeli army same rights as US troops
- What a president, a movie star, a congressman, and a cell phone all dared to say
- ‘An entire nation is being humiliated by the Iranian leadership’: Merz
- Pakistan Throws Open Its Gates for Iran’s Transit Trade to Third Countries
- Iran to charge ships passing Strait of Hormuz in rial: Lawmaker
- Talks would resume if US accepts 3-phase framework Iran put forward
- Israeli forces raid Syria’s Dara’a, Quneitra countryside, set up checkpoints
- IRGC says to reverse engineer 15 undetonated US missiles uncovered in southern Iran
- Liberation From War
- Major fire erupts at UK base used for US bombers
- If Americans Knew
- Israel escalates in Gaza: killing, torture, hunger – Daily Update
- Six Months into Gaza Ceasefire, Setting the Record Straight About Aid
- ‘Silent suffering’: Why children in Gaza are losing their ability to speak
- In Gaza, 17,000 infections linked to rodents and external parasites – Daily Update
- Lobby group taking journalists on propaganda tours of Israel
- The Shattered Figure of Jesus Is Not an Exception. It’s a Pattern
- Israel’s idea of ceasefire includes killing 21 in one day – Daily Update
- Christians in Israel and Palestine, past and present
- Israel eager to restart Iran war, Gaza genocide – Daily Update
- Meet the Top “Content” Producers Linked to Canary Mission
- No Tricks Zone
- New Study: Extreme Heat Records, Heatwaves, Extreme Cold Records Declining Across US Since 1899
- It’s The Cold, Stupid! Cold 20 Times More Lethal Than Heat, Multiple Studies Show
- European Institute For Climate And Energy: “Climate Debate is Seldom About Science”
- New Study: The Climate May Be 5 Times More Sensitive To Solar Forcing Than Commonly Assumed
- EV Industry Reached $70 Billion In Losses In 2024 Due To Delusional Green Ideologies
- Reality Check: Maldives Have Actually Grown In Size Or Remained Stable Over Recent Decades
- Abrupt Climate Change Also Occurred NATURALLY In The Past …25 Times During Last Ice Age
- Cave Discovery Reveals Today’s Desert Climates Were Recently Far Warmer, Wetter, Teeming With Life
- German Expert: Heat Dome Led To Record Temps In Western USA…Warmer In 1934, 1936
- New Study: No Linear Warming Or Glacier Retreat Along Northern Antarctic Peninsula Since 1980s
Aletho News 
